Javascript must be enabled to continue!
The PAI-1 4G/5G polymorphism, JAK2V617F mutation, and their associations with blood cells in Ph-negative myeloproliferative neoplasms
View through CrossRef
Factors influencing the urokinase-type plasminogen activator system play important roles in pathogenetic processes in Ph-negative myeloproliferative neoplasms (MPNs). In addition, the JAK2V617F mutation is a key determinant of outcomes in these diseases. This study evaluated complete blood count (CBC) parameters, the plasminogen activator inhibitor 1 (PAI-1) 4G/5G polymorphism, and the JAK2V617F mutation in patients with Ph-negative MPNs, aiming to identify possible associations between them. We analyzed results from 56 patients newly diagnosed with Ph-negative MPNs— essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF)—before treatment initiation. The CBC of 475 people from a diagnostic center database served as a population sample for comparison. In patients with Ph-negative MPNs, PAI-1 genotypes 4G/4G, 4G/5G, and 5G/5G were detected in 11 (19.6%), 29 (51.8%), and 16 (28.6%) cases, respectively. No significant differences in genotype distribution were found among ET, PV, and PMF patients. PMF patients with the 4G/5G genotype had a higher white blood cell (WBC) count compared to those with the 5G/5G genotype (P = 0.027). The JAK2V617F mutation was found in 44 (78.6%) patients. ET patients with this mutation (n = 13) exhibited significantly higher counts of platelets (PLTs), red blood cells (RBCs), and WBCs compared to those without it. The PLT/RBC ratio was significantly higher in all disease categories compared to the population sample, with the highest ratios in ET patients. The PLT/WBC ratio in ET and PV patients was also higher than in the population sample (P < 0.05). This relative thrombocytosis is likely clonal in origin, associated with genes responsible for PLT quantitative parameters, JAK-STAT signaling pathway proteins, and factors in the uPA-uPAR-PAI-1/PAI-2 system. These genes share common loci in chromosomes (1p34.1-p34.3, 7q21.1-q21.3, 9p24.1, 19p13.11-p13.2, and 19q13.31-q13.32). Due to their close spatial proximity, these genes can form genetic complexes and mutually influence their expression levels, thereby contributing to the unique pathogenesis of these diseases.
Title: The PAI-1 4G/5G polymorphism, JAK2V617F mutation, and their associations with blood cells in Ph-negative myeloproliferative neoplasms
Description:
Factors influencing the urokinase-type plasminogen activator system play important roles in pathogenetic processes in Ph-negative myeloproliferative neoplasms (MPNs).
In addition, the JAK2V617F mutation is a key determinant of outcomes in these diseases.
This study evaluated complete blood count (CBC) parameters, the plasminogen activator inhibitor 1 (PAI-1) 4G/5G polymorphism, and the JAK2V617F mutation in patients with Ph-negative MPNs, aiming to identify possible associations between them.
We analyzed results from 56 patients newly diagnosed with Ph-negative MPNs— essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF)—before treatment initiation.
The CBC of 475 people from a diagnostic center database served as a population sample for comparison.
In patients with Ph-negative MPNs, PAI-1 genotypes 4G/4G, 4G/5G, and 5G/5G were detected in 11 (19.
6%), 29 (51.
8%), and 16 (28.
6%) cases, respectively.
No significant differences in genotype distribution were found among ET, PV, and PMF patients.
PMF patients with the 4G/5G genotype had a higher white blood cell (WBC) count compared to those with the 5G/5G genotype (P = 0.
027).
The JAK2V617F mutation was found in 44 (78.
6%) patients.
ET patients with this mutation (n = 13) exhibited significantly higher counts of platelets (PLTs), red blood cells (RBCs), and WBCs compared to those without it.
The PLT/RBC ratio was significantly higher in all disease categories compared to the population sample, with the highest ratios in ET patients.
The PLT/WBC ratio in ET and PV patients was also higher than in the population sample (P < 0.
05).
This relative thrombocytosis is likely clonal in origin, associated with genes responsible for PLT quantitative parameters, JAK-STAT signaling pathway proteins, and factors in the uPA-uPAR-PAI-1/PAI-2 system.
These genes share common loci in chromosomes (1p34.
1-p34.
3, 7q21.
1-q21.
3, 9p24.
1, 19p13.
11-p13.
2, and 19q13.
31-q13.
32).
Due to their close spatial proximity, these genes can form genetic complexes and mutually influence their expression levels, thereby contributing to the unique pathogenesis of these diseases.
Related Results
PF685 THE RELATIONSHIP BETWEEN TOTAL ANTIOXIDANT CAPACITY AND JAK2V617F MUTATION IN ESSENTIAL THROMBOCYTHEMIA
PF685 THE RELATIONSHIP BETWEEN TOTAL ANTIOXIDANT CAPACITY AND JAK2V617F MUTATION IN ESSENTIAL THROMBOCYTHEMIA
Background:Essential thrombocythemia (ET) is a BCR‐ABL1‐negative myeloproliferative neoplasm associated in 50–60% of cases with the presence of the JAK2V617F mutation. Several stud...
Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice.
Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice.
Abstract
Abstract 2902
Poster Board II-878
Myeloproliferative neoplasms (MPNs) are frequent malignant hematopoietic pathologies. The ac...
The Clinical Implications of JAK2V617F Mutation in 137 Chinese Patients with Myeloproliferative Diseases.
The Clinical Implications of JAK2V617F Mutation in 137 Chinese Patients with Myeloproliferative Diseases.
Abstract
A single acquired mutation in the JAK2 gene has recently been described in the classic myeloproliferative diseases(MPDs) including 65–97% of patients with p...
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
PS1446 THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN JAK2V617F‐POSITIVE MYELOPLROLIFERATIVE NEOPLASMS
Background:Constitutive activation of the Jak/Stat signalling pathway is a hallmark of Myeloproliferative Neoplasms (MPN), with 60–90% of patients carrying the activating JAK2 muta...
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED]Guardian Blood Balance Reviews (Works Or Hoax) Does Guardian Botanicals Blood Balance AU Really Works? Read Updated Report! Diabetes and Hypertension is such a health p...
Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations
Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations
Abstract
Objective Whetherinterferon alpha (IFN-α) has special therapeutic effect formyeloproliferative neoplasm (MPN) patients with JAK2V617F mutations was not wide...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Draft Recommendations on Classification of Rodent Neoplasms for Peto Analysis
Draft Recommendations on Classification of Rodent Neoplasms for Peto Analysis
The Executive Committee of the Society of Toxicologic Pathology appointed an ad hoc working group to review the current use of the Peto model for statistical analysis of rodent car...

